Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 13-20

  Kawai, Sadayuki ^a   Kato, Shunsuke ^a   Imai, Hiroo ^a   Okada, Yoshinari ^a   Ishioka, Chikashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

A1,2 fucosyltransferase; Epidermal growth factor receptor; HER2 overexpression; Lewis Y antigen; Proliferation; Short interfering RNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUT1 PROTEIN; LEWIS Y ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EGFR GENE; FUT1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GLYCOSYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FUCOSYLTRANSFERASES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 84872839277     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2120     Document Type: Article

References (31)

1. Roseman S: Reflections on glycobiology. J Biol Chem 276: 41527-41542, 2001.
2. Liu YC, Yen HY, Chen CY, et al: Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA 108: 11332-11337, 2011.
3. Javaud C, Dupuy F, Maftah A, et al: The fucosyltransferase gene family: an amazing summary of the underlying mechanisms of gene evolution. Genetica 118: 157-170, 2003.
4. Matzhold EM, Helmberg W, Wagner T, et al: Identification of 14 new alleles at the fucosyltransferase 1, 2, and 3 loci in Styrian blood donors, Austria. Transfusion 49: 2097-2108, 2009.
5. Dettke M, Pálfi G and Loibner H: Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 68: 511-514, 2000.
6. Hokke CH, Neeleman AP, Koeleman CA and van den Eijinden DH: Identification of an a3-fucosyltransferase and a novel a2-fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: biosynthesis of the Fuca1->2Fuca1->3[Gal(NAc)ß1->4] GlcNAc sequence. Glycobiology 8: 393-406, 1998.
7. Nakagoe T, Fukushima K, Itoyanagi N, et al: Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 128: 257-264, 2002.
8. Tsuboi K, Asao T, Ide M, et al: a1,2-fucosylation is a superior predictor of postoperative prognosis for colorectal cancer compared with blood group A, B, or sialyl Lewis X antigen generated within colorectal tumor tissue. Ann Surg Oncol 14: 1880-1889, 2007.
9. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: R780-R787, 2005.
10. Arai Y and Nishida M: Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody. Int J Gynecol Cancer 13: 42-46, 2003.
11. Kim YS, Yuan M, Itzkowitz SH, et al: Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and non-malignant colonic tissues. Cancer Res 46: 5985-5992, 1986.
12. Kitamura K, Stockert E, Garin-Chesa P, et al: Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA 91: 12957-12961, 1994.
13. Iwamori M, Tanaka K, Kubushiro K, et al: Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the a1, 2-fucosyltransferase gene. Cancer Sci 96: 26-30, 2005.
14. Zhao Y, Lin B, Hao YY, et al: The effects of Lewis(y) antigen content on drug resistance to carboplatin in ovarian cancer line RMG-I. Prog Biochem Biophys 35: 1175-1182, 2008.
15. Liu JJ, Lin B, Hao YY, et al: Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep 23: 833-841, 2010.
16. Brennan PJ, Kumogai T, Berezov A, et al: HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 19: 6093-6101, 2000.
17. Slamon DJ, Godolphin W and Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
18. Gravalos C and Jimeno A: HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann Oncol 19: 1523-1529, 2008.
19. Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63-69, 2004.
20. Palumberi D, Aldi S, Ermini L, et al: RNA-mediated gene silencing of FUT1 and FUT2 influences expression and activities of bovine and human fucosylated nucleolin and inhibits cell adhesion and proliferation. J Cell Biochem 111: 229-238, 2010.
21. Chang WW, Lee CH, Lee P, et al: Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci USA 105: 11667-11672, 2008.
22. Mittendorf EA, Liu Y, Tucker SL, et al: A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29: 3896-3907, 2010.
23. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
24. Brockhoff G, Heckel B, Schmidt-Bruecken E, et al: Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 40: 488-507, 2007.
25. Patel D, Bassi R, Hooper A, et al: Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Cancer Sci 99: 1611-1617, 2008.
26. Zhang Z, Sun P, Liu J, et al: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 1783: 287-296, 2008.
27. Miyoshi E, Moriwaki K and Nakagawa T: Biological function of fucosylation in cancer biology. J Biochem 143: 725-729, 2008.
28. Wang X, Gu J, Ihara H, et al: Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 281: 2572-2577, 2006.
29. Dogan I, Cumaoglu A, Aricioglu A and Ekmekci A: Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 347: 41-51, 2011.
30. Bijman MN, van Berkel MP, Kok M, Janmaat ML and Boven E: Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. Anticancer Drugs 20: 450-460, 2009.
31. Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316: 1083-1100, 2010.